Analyzing the Potential ETF Winners & Losers from The Weight-Loss Drug Craze

How do these weight loss drugs work?

These new weight-loss drugs, though distinct in their specifics, generally work by targeting areas of the brain that regulate appetite and food intake.

Essentially, they send signals to the brain to promote feelings of fullness, which helps reduce overall calorie consumption.

Additionally, some of these drugs also slow down gastric emptying, the process by which food exits the stomach and enters the small intestine, contributing further to a sensation of fullness.

The main takeaway from the mechanism of these weight-loss drugs is straightforward: they help people eat less by enhancing the feeling of satiety.

This seemingly simple effect—consuming fewer calories—can ripple out to have significant implications for a range of companies.

Potential losers: food and beverage ETFs

For food producers and retailers, particularly those whose sales are heavily reliant on high-calorie or processed food items, the widespread adoption of such drugs could lead to decreased demand.

If weight-loss drugs like Ozempic, Wegovy, and Mounjaro become a mainstay in the market, consumer staples sector companies known for their high-calorie and prepackaged food offerings could face headwinds.

Brands may experience a shift in consumer preferences as those on these medications may opt for lower-calorie options, reducing the sales of sugary beverages, cereals, snacks, and other processed foods that have been core staples driving their top line.

For Coca-Cola, the impact might be felt in reduced sales volumes for their flagship sodas, as consumers managing their weight might pivot towards water, diet, or zero-calorie options.

General Mills might see a similar trend affecting their range of breakfast cereals and snack bars, traditionally high in sugars and carbohydrates.

PepsiCo, with its diverse array of snack foods and beverages, may have to innovate or highlight its healthier options to stay competitive.

Mondelez, known for its snack brands, could also be compelled to adjust its product strategies, emphasizing lower-calorie alternatives or new products that cater to health-conscious consumers.

In the consumer discretionary sector, restaurants such as McDonald's, Chipotle, and Domino's Pizza could face challenges, too. While these chains have been diversifying their menus to include healthier options, their core offerings are often calorie-dense.

If a significant portion of consumers begin using these weight-loss drugs, these companies might need to further adapt their menus or marketing strategies to appeal to a more health-focused clientele. This could mean a greater emphasis on salads, lean proteins, and low-carb options.

However, it's also possible that the convenience and affordability of these chains will continue to drive business from a diverse customer base, even among those seeking to manage their weight.

Industry-specific ETFs to watch here include the Invesco Food & Beverage ETF (PBJ) and the AdvisorShares Restaurant ETF (EATZ).

Potential winner: pharmaceutical ETFs

Pharmaceutical ETFs stand to be clear beneficiaries in the wake of FDA approval for new weight-loss drugs. FDA approval is a crucial step that allows pharmaceutical companies to market and sell their products in the U.S., one of the largest markets for healthcare products.

With this regulatory nod, companies like Novo Nordisk and Eli Lilly can actively promote their weight-loss drugs to doctors and consumers, expanding their consumer base significantly.

This approval can often lead to a surge in the companies' stock prices, as it not only validates the efficacy and safety of the drug but also opens the door to substantial revenue generation.

However, it's important to consider that the potential success of these drugs may already be priced in. That is, investors often anticipate FDA approvals and other significant milestones, buying into related stocks in advance, which can inflate valuations.

When it comes to the structure of ETFs, the way they are weighted is crucial in understanding how the success of a particular drug will affect the ETF's performance.

Market-cap-weighted ETFs allocate more of their assets to larger companies based on their market capitalization, meaning that the success of a blockbuster drug from a pharmaceutical giant will have a more pronounced effect on the ETF's overall performance.

This is particularly relevant for the weight-loss drugs in question, which are produced by some of the largest players in the industry. Therefore, a market-cap-weighted pharmaceutical ETF is likely to benefit more directly from the success of these drugs, as the positive financial impact on these large companies' bottom lines will be more substantially reflected in the ETF's value.

In contrast, equal-weight ETFs spread their investments more evenly across companies of varying sizes, including many small- and mid-cap firms. While this can offer more exposure to the potential high growth rates of smaller companies, it also means that the ETF is less sensitive to the performance of its largest holdings.

For investors specifically looking to capitalize on the success of weight-loss drugs from the likes of Novo Nordisk and Eli Lilly, a market-cap-weighted ETF would offer a more targeted investment strategy compared to equal-weight alternatives.

ETFs to watch here include the iShares U.S. Pharmaceuticals ETF (IHE) and the SPDR S&P Pharmaceuticals ETF (XPH).

Please note this article is for information purposes only and does not in any way constitute investment advice. It is essential that you seek advice from a registered financial professional prior to making any investment decision.